B. Riley Has Lowered Expectations for Geron (NASDAQ:GERN) Stock Price

Geron (NASDAQ:GERN) had its price target reduced by B. Riley from $5.50 to $3.50 in a research report released on Tuesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC lifted their price objective on Geron from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, January 13th. Barclays raised Geron to a “strong-buy” rating in a report on Friday, November 29th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price objective on shares of Geron in a report on Tuesday, December 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.91.

Geron Stock Up 2.5 %

NASDAQ GERN opened at $2.63 on Tuesday. The company has a current ratio of 2.89, a quick ratio of 2.74 and a debt-to-equity ratio of 0.04. The stock’s 50 day moving average is $3.19 and its two-hundred day moving average is $3.90. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of -8.20 and a beta of 0.53. Geron has a 1-year low of $1.64 and a 1-year high of $5.34.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Alternative Investment Advisors LLC. raised its position in Geron by 13.3% in the 3rd quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 2,612 shares during the last quarter. Rovin Capital UT ADV raised its position in shares of Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 3,660 shares during the last quarter. Values First Advisors Inc. raised its position in shares of Geron by 13.6% during the 3rd quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company’s stock valued at $139,000 after acquiring an additional 3,668 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Geron by 23.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 4,094 shares during the last quarter. Finally, Xponance Inc. raised its position in shares of Geron by 12.9% during the 4th quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,829 shares during the last quarter. Institutional investors own 73.71% of the company’s stock.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.